Summary
This network meta-analysis of 28 randomized controlled trials (8,770 patients) compares fluid resuscitation strategies in sepsis/septic shock. Balanced crystalloids (BC) demonstrated significant advantages, reducing 90-day mortality compared to saline (RR 0.89) and low-molecular-weight hydroxyethyl starch (L-HES; RR 0.84). Hyperoncotic albumin showed promise for renal protection but BC ranked highest overall, with superior outcomes for mortality, renal replacement therapy (RRT) avoidance, and blood transfusion needs.
Key Points:
-
1. BC reduced 90-day mortalityby 11% vs saline and 16% vs L-HES
2. BC had highest SUCRA rankingsfor:
– 90-day mortality (86.3%)
– RRT avoidance (75.5%)
– Blood transfusion reduction (72.2%)
3. Hyperoncotic albuminwas most effective for reducing AKI (SUCRA 74.5%)
4. HES solutions showed risks:
– H-HES increased RRT need vs BC (RR 0.59)
– L-HES reduced transfusions by 7% vs saline
5. No fluid significantly reduced 28-day mortality (BC ranked best at 71.4%)
6. BC’s benefits attributed to:
– Physiological electrolyte balance
– Reduced hyperchloremia risk
– Potential immunomodulatory effects
7. Current guidelines favor crystalloids but don’t specify BC – this supports refinement
8. Study limitations include:
– Heterogeneous fluid dosing across trials
– Lack of combination fluid studies
– English-language publication bias
9. All included studies were RCTs with low-moderate risk of bias
10. Findings consistent with previous NMAs but with larger sample size
Conclusion
This analysis establishes balanced crystalloids as the optimal resuscitation fluid for sepsis, demonstrating superior mortality reduction and renal protection compared to alternatives. While hyperoncotic albumin shows specific benefits for AKI prevention, BC should be the first-line choice. The results call for updated clinical guidelines to specifically recommend BC over saline and against HES solutions. Future research should address standardized dosing protocols and colloid-crystalloid combinations.
Listen to the following podcast on “Fluid Therapy for Critically Ill Adults With Sepsis” by JAMA Network Health Systems & Recruitment
Discussion Questions
1. How can healthcare systems overcome cost and logistical barriers to implement BC as the universal first-line fluid for sepsis resuscitation?
2. Should hyperoncotic albumin be incorporated into specific sepsis protocols for high-risk renal patients despite not being first-line?
3. What monitoring parameters (e.g., chloride levels, lactate clearance) could help clinicians personalize fluid choices when BC is unavailable?
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
